{"product_id":"cancer-and-inflammation-isbn-9780470855102","title":"Cancer and Inflammation","description":"Chronic inflammation predisposes to some forms of cancer and the host response to malignant disease shows several parallels with inflammation and wound healing. The cells involved in inflammation are detected in a range of common cancers, together with the inflammatory cytokines and members of the chemokine ligand\/receptor systems.\u003cbr\u003e \u003cbr\u003e Neutralization or deletion of the gene for some inflammatory cytokines confers resistance to tumour induction and experimental metastasis. Over-expression of such cytokines in tumour cells may enhance malignant potential. Certain chemokines are likely to subvert antitumour immunity by favouring development of ineffective Type 2 responses. Tumour cells may even utilize chemokine receptors in homing to lymph nodes and other organs. Thus, the cells, cytokines and chemokines found in tumours are more likely to contribute to tumour growth, progression and immunosuppression than they are to mount an effective host antitumour response.\u003cbr\u003e \u003cbr\u003e This book draws together contributions from an international group of scientists and clinicians from diverse disciplines, ranging from epidemiology to immunology, cell biology, molecular oncology, molecular medicine and pharmacology to debate these and related issues. Topics covered include the epidemiological links between cancer and inflammation, the parallels between inflammation and cancer, the role of inflammation in cancer, inflammatory genes as risk factors for cancer initiation and progression, inflammation and cancer angiogenesis, and preventative and therapeutic strategies.\u003cbr\u003e \u003cbr\u003e Related Novartis Foundation symposia:\u003cbr\u003e 252 Generation and Effector Functions of Regulatory Lymphocytes\u003cbr\u003e Chair: Jean-François Bach\u003cbr\u003e \u003cbr\u003e 254 Immunoinformatics: Bioinformatic Strategies for Better Understanding of Immune Function\u003cbr\u003e Chair: Hans-Georg Rammensee  Chair's Introduction (S. Gordon).  \u003cp\u003eInflammation and cancer: an epidemiological perspective (M. Thun, et al.).\u003c\/p\u003e \u003cp\u003eChemokine-based pathogenetic mechanisms in cancer (I. Conti, et al.).\u003c\/p\u003e \u003cp\u003eGeneral Discussion I.\u003c\/p\u003e \u003cp\u003eAnti-TNF therapy of rheumatoid arthritis: what can we learn about chronic disease? (M. Feldmann, et al.).\u003c\/p\u003e \u003cp\u003eHow do chemokine\/chemokine receptor activations affect tumorigenesis? (A. Richmond, et al.).\u003c\/p\u003e \u003cp\u003eProinflammatory cytokines, immune response and tumour progression (M. Spadaro and G. Forni).\u003c\/p\u003e \u003cp\u003eGeneral discussion II.\u003c\/p\u003e \u003cp\u003eLymphangiogenesis and tumour metastasis (J. Tille, et al.).\u003c\/p\u003e \u003cp\u003eInfiltration of tumours by macrophages and dendritic cells: tumour-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes (A. Mantovani, et al.).\u003c\/p\u003e \u003cp\u003eThe influence of CD25\u003csup\u003e+\u003c\/sup\u003e cells on the generation of immunity to tumour cell-lines in mice (E. Jones, et al.).\u003c\/p\u003e \u003cp\u003eMacrophages: modulators of breast cancer progression (E. Lin and J. Pollard).\u003c\/p\u003e \u003cp\u003eChemokines: angiogenesis and metastases in lung cancer (R. Strieter, et al.).\u003c\/p\u003e \u003cp\u003eMacrophage infiltration and angiogenesis in human malignancy (H. Knowles, et al.).\u003c\/p\u003e \u003cp\u003eThe role of  inflammation for tumour growth and tumour suppression (T. Blankenstein).\u003c\/p\u003e \u003cp\u003eCyclooxygenase 2: from inflammation to carcinogenesis (A. Ristimäki).\u003c\/p\u003e \u003cp\u003eThe inflammatory cytokine network of epithelial cancer: therapeutic implications (P. Szlosarek and F. Balkwill).\u003c\/p\u003e \u003cp\u003e\u003ci\u003eIn vivo\u003c\/i\u003e manipulation of DC migration and activation to elicit anti-tumour immunity (A. Vicari, et al.).\u003c\/p\u003e \u003cp\u003eFinal general discussion.\u003c\/p\u003e \u003cp\u003eConcluding remarks (S. Gordon).\u003c\/p\u003e \u003cp\u003eIndex of contributors.\u003c\/p\u003e \u003cp\u003eSubject Index.\u003c\/p\u003e  \"This book…is highly informative, very up-to-date, and demonstrates the complex biochemical events that may result in carcinogenesis.\" (\u003ci\u003eDoody's Electronic Journal\u003c\/i\u003e)  \u003cp\u003e“…a useful guide to the considered thoughts of those within their field.” (The Newsletter of the British Society of Cell Biology, Summer 2005)\u003c\/p\u003e  The Novartis Foundation is an international scientific and educational charity which promotes the study and general knowledge of science and in particular encourages international co-operation in scientific research.  \u003cp\u003e\u003cb\u003eChair:\u003c\/b\u003e SIAMON GORDON, Sir William Dunn School of Pathology, University of Oxford, UK\u003c\/p\u003e  Chronic inflammation predisposes to some forms of cancer and the host response to malignant disease shows several parallels with inflammation and wound healing. The cells involved in inflammation are detected in a range of common cancers, together with the inflammatory cytokines and members of the chemokine ligand\/receptor systems. Neutralization or deletion of the gene for some inflammatory cytokines confers resistance to tumour induction and experimental metastasis. Over-expression of such cytokines in tumour cells may enhance malignant potential. Certain chemokines are likely to subvert antitumour immunity by favouring development of ineffective Type 2 responses. Tumour cells may even utilize chemokine receptors in homing to lymph nodes and other organs. Thus, the cells, cytokines and chemokines found in tumours are more likely to contribute to tumour growth, progression and immunosuppression than they are to mount an effective host antitumour response.  \u003cp\u003eThis book draws together contributions from an international group of scientists and clinicians from diverse disciplines, ranging from epidemiology to immunology, cell biology, molecular oncology, molecular medicine and pharmacology to debate these and related issues. Topics covered include the epidemiological links between cancer and inflammation, the parallels between inflammation and cancer, the role of inflammation in cancer, inflammatory genes as risk factors for cancer initiation and progression, inflammation and cancer angiogenesis, and preventative and therapeutic strategies.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e\u003ci\u003eRelated Novartis Foundation symposia:\u003c\/i\u003e\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e252 Generation and effector functions of regulatory lymphocytes\u003c\/p\u003e \u003cp\u003eChair: Jean-François Bach\u003c\/p\u003e \u003col start=\"254\"\u003e \u003cli\u003eImmunoinformatics: bioinformatic strategies for better understanding of immune function\u003c\/li\u003e \u003c\/ol\u003e \u003cp\u003eChair: Hans-Georg Rammensee\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47988880507109,"sku":"NP9780470855102","price":253.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470855102.jpg?v=1761781896","url":"https:\/\/k12savings.com\/es\/products\/cancer-and-inflammation-isbn-9780470855102","provider":"K12savings","version":"1.0","type":"link"}